Pragmatic Clinical Trial to Assess the Effectiveness of Pharmaceutical Intervention in Patients With Uncontrolled Asthma
- Disease/Condition
- Asthma
- Drug/Device/Intervention
- pharmaceutical intervention
- Study type
- Interventional
- Intervention type
- behavioral
- Primary sponsor
- Hospital de Clinicas de Porto Alegre
- Location
- Porto Alegre, Brazil
- Phase
- N/A
- Start date
- Aug 14, 2023
- End date
- Mar 30, 2026
- Enrollment
- 76 participants
Asthma control
The aim of this study is to evaluate the effectiveness of pharmaceutical intervention in
 controlling asthma in patients diagnosed with uncontrolled asthma. This is a pragmatic
 clinical trial composed of two groups - intervention (pharmaceutical monitoring) and control
 (without pharmaceutical monitoring). The study population will consist of patients with
 uncontrolled asthma, seen at the asthma outpatient clinic of the Hospital de Clínicas de
 Porto Alegre. Patients who agree to participate in the study will be randomized to the
 control group (managed by the specialized outpatient medical team) and the intervention group
 (in addition to management by the specialized medical team, they will be referred for
 pharmaceutical monitoring at the Clinical Research Center of the Hospital de Clínicas de
 Porto Alegre). The primary outcome of the study will be the proportion of patients with
 uncontrolled asthma who achieve an ACT 20 after a systematic educational intervention,
 guided by a pharmaceutical professional, compared to a group that does not receive this type
 of intervention.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06227793
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06227793 through Pure Global AI's free database. This phase not specified trial is sponsored by Hospital de Clinicas de Porto Alegre and is currently Recruiting. The study focuses on Asthma. Target enrollment is 76 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.